Topsham, ME

New England Cancer Specialists

Carcinoma

Renal Cell Carcinoma

Prostatic Cancer

Transitional Cell Carcinoma

Androgen

Avelumab

Axitinib

Enfortumab

Sunitinib

Alliance Foundation Trials

Astellas

Pfizer

condition

allSponsorName

Janssen (J&J Innovative Medicine)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

New England Cancer Specialists | Topsham, ME

Site insights

Work at this site?

Active trials

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Trial sponsors